Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies

Lung Cancer - Tập 76 - Trang 177-182 - 2012
Fenlai Tan1, Xiaoyan Shen1, Dechang Wang2, Guojian Xie3, Xiaodong Zhang3, Lieming Ding1, Yunyan Hu1, Wei He1, Yanping Wang1, Yinxiang Wang1
1Zhejiang Beta Pharma Inc., R&D Center, 1 North Disheng St., 29, BPUSP, Beijing 100176, China
2Cancer Institute and Hospital, Chinese Academy of Medical Sciences, 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China
3Beta Pharma Inc., 31 Business Park Drive, Branford, CT 06405-2977, USA

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

Lung Cancer

Tập 76

177-182

Thông tin tác giả